产品详情
Targets
Target | Value |
---|---|
VEGFR1/FLT1 | IC50: 3nM |
CSF-1R | IC50: 3nM |
VEGFR2/KDR | IC50: 4nM |
FLT3 | IC50: 4nM |
Kit | IC50: 14nM |
PDGFRβ | IC50: 66nM |
Tie-2 | IC50: 170nM |
VEGFR3/FLT4 | IC50: 190nM |
SGK | IC50: 940nM |
RET | IC50: 1.9μM |
PKA | IC50: 5.9μM |
Cdc2 | IC50: 9.8μM |
FGFR | IC50: >12.5μM |
Lyn | IC50: >20μM |
LCK | IC50: 38μM |
Src | IC50: >50μM |
IGFR | IC50: >50μM |
INSR | IC50: >50μM |
EGFR | IC50: >50μM |
Hck | IC50: >50μM |
c-Met | IC50: >50μM |
Fyn | IC50: >50μM |
FGR | IC50: >50μM |
Akt | IC50: >50μM |
In vitro (25°C) | DMSO | 73 mg/mL (194.45 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 5%DMSO+40%PEG 300+5%Tween80+50%ddH2O | 9 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 26.64 mL | 133.19 mL | 266.38 mL |
0.5 mM | 5.33 mL | 26.64 mL | 53.28 mL |
1 mM | 2.66 mL | 13.32 mL | 26.64 mL |
5 mM | 0.53 mL | 2.66 mL | 5.33 mL |
*The above data is based on the productmolecular weight 375.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10025 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 375.4 |
Formula | C21H18FN5O |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 796967-16-3 |
Synonyms | ABT869, ABT-869 |
SMILES | CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N |
1. Zhou J, Khng J, Jasinghe VJ, Bi C, Neo CH, Pan M, Poon LF, Xie Z, Yu H, Yeoh AE, Lu Y, Glaser KB, Albert DH, Davidsen SK, Chen CS: In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leuk Res. 2008 Jul;32(7):1091-100. Epub 2007 Dec 26. [PubMed:18160102 ]
2. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. [PubMed:16648572 ]
3. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006. [PubMed:16648571 ]
产品标签
Product Questions
Product Questions
Raf265 derivative
Raf265 derivative是Raf265的衍生物,Raf265是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,IC50为5至10μM。
Buflomedil HCl
Buflomedil HCl是一种用于治疗外周血管疾病的血管活性剂。
Flumatinib mesylate
Flumatinib mesylate以时间和剂量依赖性的方式降低U266细胞中C-MYC,HIF-1a和VEGF的表达,因此甲磺酸氟马替尼可能…
TSU-68 (Orantinib, SU6668)
TSU-68 (Orantinib,SU6668)在无细胞试验中具有8 nM的Ki对PDGFR自磷酸化的最大效力,但也强烈抑制Flk-1和FGFR1反磷酸…
Pazopanib HCl (GW786034)
Pazopanib HCl (GW786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可…
SU 5416 (Semaxinib)
SU 5416 (Semaxinib)是血管内皮生长因子受体(VEGFR)的抑制剂,它还抑制其他酪氨酸激酶KIT,MET,FLT3和RET。
BMS-817378
BMS-817378是Met/VEGFR-2双重抑制剂BMS-794833的新型前药。